Niets uit deze uitgave mag worden verveelvoudigd, opgeslagen in een geautomatiseerd gegevensbestand of openbaar gemaakt worden in enige vorm of op enige wijze, hetzij elektronisch, mechanisch of door fotokopieen, opname, of op enige andere manier, zonder voorafgaande schriftelijke toestemming van de auteur.
dIabetIc macular edema
The pathogenesis of DME is not fully understood. Although the breakdown of the BRB is considered to be a major mechanism in the development of DME, other mechanisms may include capillary non-perfusion, neuronal damage, and alterations of the vitreous gel 9 . Vascular Endothelial Growth Factor (VEGF) is a major mediator of proangiogenic factors which may produce DME by altering endothelial tight junctions and transcellular flow 5 . Intraocular delivery of anti-VEGF therapies are now used widely in the treatment of DME. However, it is estimated that about 50% of DME patients are refractory to anti-VEGF therapies 10, 11 .
At present, robust biomarkers to identify which DME patients are potential good and nonresponders to anti-VEGF therapies have not been established.
necessIty of bIomarkers for dr
The global rise in diabetes will result in 552 million individuals being affected by this chronic sight-threatening disease by the year 2030 12 . By the year 2050, 1 in 3 persons in the United
States are projected to have diabetes, with approximately half having some degree of DR at any point in time 13 . Thus, ocular complications from diabetes are a major and expanding public health concern. There is a critical need to identify biomarkers for DR 14 . Although anti-VEGF agents are effective, there is a need for the substantial proportion of patients who do not respond completely to anti-VEGF therapy 11 . One difficulty that prevents the development of new treatments is the identification of robust biomarkers of DR that could help define targets for new therapies or provide more effective management strategies 15 . Another is the prolonged period needed to assess changes in vision and progression of disease by fundus photography. Associations found to date are generally not sensitive or specific enough to be reliable biomarkers for DR 16 . 20 . Specific OCT patterns have been reported to be predictive of outcome after anti-VEGF therapy. Patients with cystoid macular edema (CME) pattern have been found to achieve better visual acuity and greater changes in retinal thickness after anti-VEGF therapy, while patients with diffuse pattern have been reported to exhibit a less favorable outcome [21] [22] [23] .
ImagIng bIomarkers for dr
In addition to specific OCT patterns, anatomic characteristics such as the presence of highly reflective spots, disruption of inner/outer retinal layers and intraretinal cysts have been suggested to be relevant features in predicting the response of DME patients to anti-VEGF therapies [24] [25] [26] [27] [28] . processes involved in DR has offered approaches to select candidate circulating biomarkers based on pathogenic mechanism and structural damage. Recently, a number of circulating biomarkers associated with pathogenic mechanisms and structural retinal tissue damage of DR have been independently and significantly associated with DR [34] [35] [36] [37] [38] [39] . Endothelial progenitor cells are circulating cells that have been suggested to play roles in the regeneration of vessel damage and may be involved in the pathogenesis of DR 35, 36, 40, 41 . Other candidate biomarkers are related to structural damage of the retina in DR 34, 38, 39, 42 . However, little is known about the potential value of these biomarkers in patients with DME. In addition to further research investigating the potential of these biomarkers, it is essential to investigate potential VEGFindependent mechanisms of DME, such as the plasma kallikrein kinin system (KKS).
kallIkreIn kInIn system
The KKS has been discovered by Feener and colleagues as a potential mediator of BRB loss and VEGF-independent mechanism of DME [43] [44] [45] [46] [47] [48] [49] . Plasma kallikrein is activated by the coagulation factor XIIa, which is released by the contact system during inflammation and bleeding 47 . Once generated, plasma kallikrein divides high molecular weight kininogen to produce bradykinin, which can stimulate vasoactive hormones (e.g. nitric oxide) that influence the BRB 48 . Components of the KKS, including plasma kallikrein and factor XII, have been identified in the vitreous fluid of patients with DME 44 . These findings suggest that components of the KKS in plasma may be potential biomarkers in patients with DME.
aIm of the thesIs
The aim of the thesis is to identify potential novel biomarkers for DR. Identification of potential novel biomarkers for DR could contribute to the definition of targets for new therapies and provide more effective management strategies for DR.
outlIne of the thesIs
Components of the KKS may be potential biomarkers for DR. In Chapter 1a, we review the In Chapter 3a, we determined whether specific circulating biomarkers could be used as potential markers for patients with DME that receive anti-VEGF therapy. The candidate biomarkers were selected based on literature on structural damage and pathogenic mechanism of DR and included mRNA levels of CD34+, CD133+, rhodopsin, RPE65, and retinoschisin.
Blood samples were collected at baseline in a cohort of patients from the BRDME study and OCT images and visual acuity were analyzed during anti-VEGF treatment to assess the associations between candidate markers and changes in retinal thickness and visual acuity. 
